Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scotts Miracle-Gro

Top Ancillary and Medical Pot Stocks Right Now? The post Top Medical and Ancillary Marijuana Stocks For Q4 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Medical and Ancillary Marijuana Stocks For Q4 2022

Aflac

Hormel Foods

All three of the stocks are Dividend Aristocrats.

3 Dividend Stocks That Could Pay You for the Rest of Your Life

Kimberly-Clark

NextEra Energy

Realty Income Corp

The market continues its downward trend. The U.S. Federal Reserve is raising interest rates in response to high inflation.

4 Dividend Stocks Yielding 4%+

Altria

Dividend kings are elite stocks that have raised dividends for at least 50 consecutive years. Naturally, their track record attracts pickers of top income stocks. Below, I show how we screen the dividend kings for two actionable best ideas, one each for high-yield and dividend growth investors.

Top Dividend King Stocks To Watch - Our Favorites Are Altria And AbbVie

DexCom

Don't forget these companies when you're investing in the next bear market.

2 Top Stocks to Buy in October and Hold Forever

Abbott Labs

It's parent vs. child in this bear-market matchup.

Better Bear-Market Buy: Abbott Laboratories vs. AbbVie Stock

Axsome Therapeutics

Biogen

Exelixis

Eli Lilly

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure.

These 7 Biotech Stocks Are Set to Boom in 2023

L3Harris

Northrop Grumman

Dividend growth stocks are my favorite investment category – no matter what kind of economic cycle we're in. I can collect (or, better yet, reinvest) their payouts even when the market is going through volatility.

3 Dividend Growth Stocks To Fight Inflation

Johnson & Johnson

Merck

Their dividends should be much bigger in the future.

3 Great Dividend Stocks to Buy in October

Freeport-McMoRan

Alphabet

QUALCOMM

Raytheon Technologies

Teck Resources

Tesla

A bear market is the worst time to buy growth stocks. Volatility spooks investors, and current fears around inflation and higher interest rates also hurt the story.

7 Growth Stocks to Buy and Hold for the Next 10 Years

Black Hills

Federal Realty Investment Trust

Coca-Cola

Northwest Natural Gas

At 24/7 Wall St., we know how important dividend size, stability and growth are to growth and income investors who need a dependable stream of passive income.

7 ‘Strong Buy' Dividend Kings to Grab Now in Case a Total Market Meltdown Is Coming

Apple

Bank of America

iShares Core Dividend Growth ETF

Humana

JPMorgan Chase & Co

Morgan Stanley

Microsoft

iShares Short Maturity Bond ETF

Pfizer

iShares 1-3 Year Treasury Bond ETF

Funds investing in short-term Treasury bonds may be the best ETFs for investors in today's seesawing markets. The post Short-Term Treasury Rates Boost Appeal Of Bond ETFs appeared first on Investor's Business Daily.

Short-Term Treasury Rates Boost Appeal Of Bond ETFs

The stock market is rolling over as the third quarter comes to a close. The S&P 500 is down 21% year-to-date (YTD) as of this writing.

Best Stocks 2022: What's Not to Like About AbbVie (ABBV) Stock?

CVS Health

The payouts these companies distribute every quarter could surge over the next several years.

3 Dividend Stocks to Buy In October and Hold Forever

Mastercard

NVIDIA

Walmart

September has historically been the weakest month for the U.S. stock market, and 2022 was no different.

These Were The Five Best And Worst Performing Mega-Cap Stocks In September 2022

Broadcom

Exxon Mobil

Living through bear markets sure can be tough. Such environments can create a lot of emotional turmoil, heartache and painful losses.

3 Cheap Stocks to Buy for Their High Cash Flow and Dividends

NORTH CHICAGO, Ill. , Oct. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens.

AbbVie to Host Third-Quarter 2022 Earnings Conference Call

American Electric Power Company

PPG Industries

Rockwell Automation

Making sure that income stream grows is critical. Without growth, your dividend income stream will lose purchasing power to inflation.

Five Expected Dividend Increases In October 2022

Accenture Plc

A. O. Smith

Amphenol

BancFirst

Brady Corporation

Brown & Brown

Many of the dividend increases in September were modest. One exception was Accenture, which rewarded investors with a 15% boost. Utilities New Jersey Resources and OGE rewarded investors with boosts in the high single digits.

AbbVie, Rockwell Among 18 Companies To Announce Annual Dividend Increases In October

News for AbbVie Stock (ABBV)